Risankizumab, Andexanet Alfa & GSK’s IV Zanamivir Up For CHMP Opinion
Executive Summary
Opinions on whether new products for the treatment of conditions such as psoriasis, coagulation reversal, flu and diabetes should be granted an EU marketing authorization are due this week as the EMA’s key scientific committee, the CHMP, meets for the last time in London..